CD274 and colorectal cancer: For example, in colorectal cancer patients, only 5% of the population belongs to MSI-high type, while the majority of the population—around 95%—has microsatellite-stable (MSS) or MMR-proficient disease, and does not response to PD-1/PD-L1 based immunotherapy1.